AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01951989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiglucérase (drug) pharmacokinetics
Study NCT01335256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1000394
Description: BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
Study NCT02521870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Study NCT02332993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: FPP
Description: Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
Study NCT01071499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.1 mg/kg)
Study NCT01071499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.2 mg/kg)
Study NCT01071499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.3 mg/kg)
Study NCT00372619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days
Study NCT02292004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL Reconstruction
Description: Standard surgical reconstruction of the ACL with autograft hamstring tendon
Study NCT01268306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B+L Biotrue MPS and B+L PureVision
Description: Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
Study NCT02499159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine
Description: 266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
Study NCT02499159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% standard bupivicaine
Description: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
Study NCT02438059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SoSu-liv website and app
Description: A 38 weeks web- and app-based tool for lifestyle changes intervention.
Study NCT01532388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eScreen
Description: Web based self-monitoring of problematic alcohol and drug use.
Study NCT02521870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SD-101(3)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
Study NCT02288897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Study NCT04755179 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate
Study NCT04755179 — intervention group
Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate
Study NCT04755179 — intervention group
Intervention type: PROCEDURE
Intervention: Non-operative treatment
Description: Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children > 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical.
Study NCT04755179 — intervention group
Intervention type: PROCEDURE
Intervention: Direct appendectomy
Description: laparoscopic or open appendectomy as described
Study NCT01105234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.
Study NCT04425863 — intervention group
Intervention type: DRUG
Intervention: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets
Description: 24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
Study NCT04425863 — intervention group
Intervention type: OTHER
Intervention: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets
Description: 36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
Study NCT04425863 — intervention group
Intervention type: OTHER
Intervention: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
Description: 48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
Study NCT01728766 — intervention group
Intervention type: OTHER
Intervention: Small for gestational age at delivery
Description: Small for gestational age at delivery. gestational age at >37 weeks by and birth weight \<2500 g
Study NCT00372619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00995631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral lipectomy
Description: Standard (non-experimental) suction assisted liposuction surgery
Study NCT03484741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC and PRP
Description: MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
Study NCT02297919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of Internet Based Obesity Control Programme
Study NCT02288897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine, temozolomide or talimogene laherparepvec
Study NCT02297919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of Internet Based Obesity Control Programme
Study NCT03656211 — intervention group
Intervention type: OTHER
Intervention: Telephone interview
Description: Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview.
Study NCT01728766 — intervention group
Intervention type: OTHER
Intervention: Post-term Infant, Not Heavy-for-dates
Description: Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
Study NCT00840385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAD
Description: Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
Study NCT01312285 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resonator device
Description: low level magnetic fields
Study NCT01312285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resonator device
Description: low level magnetic fields
Study NCT02253680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actico, short-stretch, inelastic dressing
Description: Worn 24hr post-operatively
Study NCT04366739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHLORPROMAZINE (CPZ)
Description: Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum
Study NCT04366739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm
Study NCT04366739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm
Study NCT02132689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actilyse (Thrombolytic therapy)
Study NCT02132689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparine (Standard anticoagulation therapy)
Study NCT00372619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage
Study NCT00939341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort (Budesonide/Formoterol)
Description: Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Study NCT04501965 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine/Azithromycine
Description: Dual treatment with Hydroxychloroquine and Azythromycin
Study NCT04501965 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quinquina-Stevia/Azythromycin
Description: Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
Study NCT04501965 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 4Plants/Azythromycin
Description: Dual treatment with 4 plant species drug and Azythromycin
Study NCT02455843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Patients assigned to the combination group will be treated with microwave in the primary tumor site
Study NCT02455843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microwave ablation
Description: Patients assigned to the combination group will be treated with microwave in the primary tumor site
Study NCT01834638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: capsule(s)
Study NCT02141529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar pulsed radiofrequency thermocoagulation
Description: Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
Study NCT02141529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar pulsed radiofrequency thermocoagulation
Description: Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
Study NCT01408732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Description: 3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
Study NCT01408732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Normal standard of care followed by Drug interevention
Study NCT02844322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Study NCT02844322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Study NCT02411773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate > 30).
Study NCT03471130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 Low dose
Description: Oral, 7 days
Study NCT03471130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 High dose
Description: Oral, 7 days
Study NCT03471130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral, 7 days
Study NCT03748888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min.
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elsubrutinib
Description: Capsule; Oral
Study NCT02411773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-4 placebo pills will be given out prior to each exercise or stretching session.
Study NCT02411773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2-4 placebo pills will be given out prior to each exercise or stretching session.
Study NCT02411773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
Study NCT00372619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT02411773 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control to Exercise (Stretching)
Description: Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
Study NCT02411773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control to Exercise (Stretching)
Description: Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for elsubrutinib
Description: Capsule; Oral
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for elsubrutinib
Description: Capsule; Oral
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet; Oral
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for upadacitinib
Description: Film-coated tablet; Oral
Study NCT03978520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for upadacitinib
Description: Film-coated tablet; Oral
Study NCT02418364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo reflexology treatment
Description: Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
Study NCT02418364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology treatment
Description: Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
Study NCT03103737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) and Reminiscence Intervention
Description: First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
Study NCT01288105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom >95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
Study NCT01364948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil application
Description: Four ml coconut oil application twice daily for first week
Study NCT01364948 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No oil application
Description: Oil application was not done
Study NCT03733132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Metformin treatment of 2500mg for 10 months in the Metformin group
Study NCT03733132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment of identical tablets to metformin group
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 1
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 2
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 3
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study NCT02233647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
Study NCT02233647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
Study NCT02233647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.